CoChat
Sign Up
Cited by 71Hormonal and reproductive studiesDementia and Cognitive Impairment ResearchMenopause: Health Impacts and Treatments

Testosterone Treatment of Men With Mild Cognitive Impairment and Low Testosterone Levels

Open access
Cherrier, M. M., Anderson, K., Shofer, J., Millard, S., Matsumoto, A. M.·2015·American Journal of Alzheimer's Disease & Other Dementias®
DOI 10.1177/1533317514556874PMC PMC10852633
Open this paper in CoChat — free accountOpen PDF

Abstract

Introduction: This study investigated the effects of testosterone (T) treatment on cognition, mood, and quality of life in men with mild cognitive impairment (MCI) and low serum T levels. Methods: A total of 351 community-dwelling men were screened, and 37 men evidenced both MCI and low T of whom 27 agreed for further screening. Twenty-two met all the study inclusion/exclusion criteria and enrolled in a 6-month randomized, double-blind, placebo-controlled study. Results: Total T levels significantly increased in the T treatment group. No significant changes were observed in measures of cognition, mood, or quality of life other than improvement in 1 objective measure of verbal memory ( P < .05) and decreased depression symptoms ( P < .02) in the treatment group. Conclusions: Testosterone treatment may modestly improve verbal memory and depression symptoms in men with both MCI and low T.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1533317514556874

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The evidence is less conclusive as to whether testosterone therapy improves cognitive function, measures of diabetes, energy, fatigue, lipid profiles, and quality of life measures.

    “The evidence is less conclusive as to whether or not testosterone therapy improves cognitive function, 28 measures of diabetes, 29 energy, 30 fatigue, 30 lipid profiles, 29 and quality of life measures. 31”

    From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [28]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 49 · Cited by 71

Research works printed but not linked: 40

  1. Hogervorst E, Bandelow S, Combrinck M, Smith AD. Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol. 2004;39(11-12):1633-1639.
  2. Moffat SD, Zonderman AB, Metter EJ, Smith AD. Free testoster- one and risk for Alzheimer disease in older men. Neurology. 2004;62(2):188-193.
  3. Chu LW, Tam S, Lee PW, et al. Bioavailable testosterone is asso- ciated with a reduced risk of amnestic mild cognitive impairment in older men. Clin Endocrinol (Oxf). 2008;68(4):589-598.
  4. Chu LW, Tam S, Wong RL, et al. Bioavailable testosterone pre- dicts a lower risk of Alzheimer's disease in older men. J Alzhei- mers Dis. 2010;21(4):1335-1345.
  5. Morley JE, Kaiser F, Raum WJ, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: Progessive decreases in bioavailable testosterone, dehy- droepiandrosterone sulfate, and the ratio of insulin-like growth factor to 1 growth hormone. Proc Natl Acad Sci U S A. 1997; 94(14):7537-7542.
  6. Cherrier MM, Asthana S, Baker LD, et al. Testosterone supple- mentation improves spatial and verbal memory in healthy older men. Neurology. 2001;57(1):80-88.
  7. Gray PB, Singh AB, Woodhouse LJ, et al. Dose-dependent effects of testosterone on sexual function, mood and visuospatial cogni- tion in older men. J Clin Endocrinol Metab. 2005;90(7): 3838-3846.
  8. Maki PM, Ernst M, London ED, et al. Intramuscular testosterone treatment in elderly men: evidence of memory decline and altered brain function. J Clin Endocrinol Metab. 2007;92(11):4107-4114.
  9. Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci. 2004, 59(1):75-78.
  10. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194.
  11. Saunders AM, Strittmatter WJ, Schmechel D, et al. Associa- tion of apolipoprotein E allele epsilon 4 with late-onset famil- ial and sporadic Alzheimer's disease. Neurology. 1993;43(8): 1467-1472.
  12. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grund- man M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007;64(9):1323-1329.
  13. Beglinger LJ, Gaydos B, Tangphao-Daniels O, et al. Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsychol. 2005;20(4):517-529.
  14. Sullivan K. Alternate forms of prose passages for the assessment of auditory-verbal memory. Arch Clin Neuropsychol. 2005;20(6): 745-753.
  15. Mitrushina M, Satz P, Chervinsky A, D'Elia L. Performance of four age groups of normal elderly on the Rey Auditory-Verbal Learning Test. J Clin Psychol. 1991;47(3):351-357.
  16. Tiernan KN, Schenk K, Swadberg D, et al. Puget sound route learning test: examination of the validity and reliability of a novel route test in healthy older adults and Alzheimer's disease patients. Clin Psychol. 2004;8(1):39-42.
  17. Malec JF, Ivnik RJ, Smith GE, et al. Visual spatial learning test: normative data and further validation. Psychol Assess. 1992;4(4): 433-441.
  18. Spreen O, Strauss E. A compendium of neuropsychological tests. New York, NY: Oxford University Press; 1991.
  19. Troyer AK, Rich JB. Psychometric properties of a new metamem- ory questionnaire for older adults. J Gerontol B Psychol Sci Soc Sci. 2002;57(1):P19-P27.
  20. Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull. 1988;24(4):709-711.
  21. Page ST, Hirano L, Gilchriest J, et al. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol. 2011;186(1):191-197.
  22. Fukai S, Akishita M, Yamada S, Toba K, Ouchi Y. Effects of tes- tosterone in older men with mild-to-moderate cognitive impair- ment. J Am Geriatr Soc. 2010;58(7):1419-1421.
  23. Vaughan C, Goldstein FC, Tenover JL. Exogenous testosterone alone or with finasteride does not improve measurements of cog- nition in healthy older men with low serum testosterone. J Androl. 2007;28(6):875-8821.
  24. Kenny AM, Bellantonio S, Gruman CA, Acosta RD, Prestwood KM. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable tes- tosterone levels. J Gerontol A Biol Sci Med Sci. 2002;57(5): M321-M325.
  25. Cherrier MM, Matsumoto AM, Amory JK, et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005;64(12):2063-2068.
  26. Cherrier MM, Asthana S, Plymate S, et al. Testosterone supple- mentation improves spatial and verbal memory in healthy older men. Neurology. 2001;57(1):80-88.
  27. Hawley WR, Grissom EM, Martin RC, Halmos MB, Bart CL, Dohanich GP. Testosterone modulates spatial recognition mem- ory in male rats. Horm Behav. 2013;63(4):559-565.
  28. Tan RS, Pu SJ. A pilot study on the effects of testosterone in hypo- gonadal aging male patients with Alzheimer's disease. Aging Male. 2003;6(1):13-17.
  29. Lu PH, Masterman DA, Mulnard R, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006;63(2):177-185.
  30. Rosario ER, Carroll JC, Oddo S, LaFerla FM, Pike CJ. Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J Neurosci. 2006;26(51): 13384-13389.
  31. Gandy S, Almeida OP, Fonte J, et al. Chemical andropause and amyloid-beta peptide. JAMA. 2001;285(17):2195-2196.
  32. Ramsden M, Nyborg AC, Murphy MP, et al. Androgens modulate B-amyloid levels in male rat brain. J Neurochem. 2003;87(4): 1052-1055.
  33. Pike CJ, Rosario ER, Nguyen TV. Androgens, Aging, and Alzheimer's Disease. Endocrine. 2006;29(2):233-241.
  34. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87(11):5001-5007.
  35. Chodosh J, Kado DM, Seeman TE, Karlamangla AS. Depressive symptoms as a predictor of cognitive decline: MacArthur Studies of Successful Aging. Am J Geriatr Psychiatry. 2007;15(5):406-415.
  36. Richard E, Schmand B, Eikelenboom P, et al. Symptoms of apathy are associated with progression from mild cognitive impairment to Alzheimer's disease in non-depressed subjects. Dement Geriatr Cogn Disord. 2012;33(2-3):204-209.
  37. Shores MM, Moceri VM, Gruenewald DA, Brodkin KI, Matsu- moto AM, Kivlahan DR. Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit. J Am Geriatr Soc. 2004;52(12):2077-2081.
  38. Seidman SN, Weiser M. Testosterone and mood in aging men. Psychiatr Clin North Am. 2013;36(1):177-182.
  39. Basaria S, Davda MN, Travison TG, Ulloor J, Singh R, Bhasin S. Risk factors associated with cardiovascular events during testos- terone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2013;68(2):153-160.
  40. Schoenfeld MJ, Shortridge E, Cui Z, Muram D. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis. J Sex Med. 2013;10(5):1401-1409.

Authors
Cherrier, M. M., Anderson, K., Shofer, J., Millard, S., & Matsumoto, A. M.
Affiliations
  • University of Washington (US)
  • VA Puget Sound Health Care System (US)
Corresponding author
Cherrier, M. M.
ORCID
Venue
American Journal of Alzheimer's Disease & Other Dementias®
Publisher
SAGE Publications
Published
2014-11-11
Volume
30
Issue
4
Pages
421-430
ISSN
  • 0888-4897 (ISSN-L)
  • 1533-3175
  • 1938-2731
DOI
10.1177/1533317514556874
PMC
PMC10852633
OpenAlex
W2007340922
Cited by
71
References
49
Citations by year
2026: 2 · 2025: 2 · 2024: 9 · 2023: 7 · 2022: 4 · 2021: 2 · 2020: 12 · 2019: 8 · 2018: 8 · 2017: 8 · 2016: 7 · 2015: 2
FWCI
4.56
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • American Journal of Alzheimer s Disease & Other Dementias® (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • Abbott Laboratories
  • University of Washington
  • National Institute on Aging (R01AG027156, AG027156)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
testosterone replacement therapy, androgen deficiency, mild cognitive impairment, men, verbal memory, depressive symptoms, quality of life, mood, cognitive function
MeSH terms
Aged, Aged, 80 and over, Depression, Double-Blind Method, Humans, Male, Memory, Middle Aged, Quality of Life, Testosterone, Treatment Outcome, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review